HLA-Ig-based artificial antigen-presenting cells: Setting the terms of engagement

Clinical Immunology

Volumn 110, Issue 3, 2004, Pages 243-251

  Oelke, Mathias ^a   Schneck, Jonathan P ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adoptive immunotherapy; CD8+ CTL; Class I HLA; HLA Ig dimer; Infectious diseases; Tumors

Indexed keywords

CANCER VACCINE; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN G; PEPTIDE; POLYMER; STREPTAVIDIN;

ACTIVE IMMUNIZATION; ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; HLA SYSTEM; HUMAN; IMMUNE SYSTEM; IMMUNOTHERAPY; MOLECULE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VACCINATION;

EID: 1642545118     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clim.2003.11.014     Document Type: Article

References (45)

1. Corr M., Slanetz A.E., Boyd L.F., Jelonek M.T., Khilko S., al-Ramadi B.K., Kim Y.S., Maher S.E., Bothwell A.L., Margulies D.H. T cell receptor-MHC class I peptide interactions: affinity, kinetics, and specificity. Science. 265:1994;946-949.
2. Matsui K., Boniface J.J., Reay P.A., Schild H., Fazekas de St Groth B., Davis M.M. Low affinity interaction of peptide-MHC complexes with T cell receptors. Science. 254:1991;1788-1791.
3. Davis M.M., Chien Y. Topology and affinity of T-cell receptor mediated recognition of peptide-MHC complexes. Curr. Opin. Immunol. 5:1993;45-49.
4. Boniface J.J., Rabinowitz J.D., Wulfing C., Hampl J., Reich Z., Altman J.D., Kantor R.M., Beeson C., McConnell H.M., Davis M.M. Initiation of signal transduction through the T cell receptor requires the multivalent engagement of peptide/MHC ligands. (corrected) Immunity. 9:1998;459-466.
5. Altman J.D., Moss P.A., Goulder P.J., Barouch D.H., McHeyzer-Williams M.G., Bell J.I., McMichael A.J., Davis M.M. Phenotypic analysis of antigen-specific T lymphocytes. Science. 274:1996;94-96.
6. Greten T.F., Slansky J.E., Kubota R., Soldan S.S., Jaffee E.M., Leist T.P., Pardoll D.M., Jacobson S., Schneck J.P. Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19-specific CD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients. Proc. Natl. Acad. Sci. U. S. A. 95:1998;7568-7573.
7. Lee P.P., Yee C., Savage P.A., Fong L., Brockstedt D., Weber J.S., Johnson D., Swetter S., Thompson J., Greenberg P.D., Roederer M., Davis M.M. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5:1999;677-685.
8. Dal Porto J., Johansen T.E., Catipovic B., Parfiit D.J., Tuveson D., Gether U., Kozlowski S., Fearon D.T., Schneck J.P. A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations. Proc. Natl. Acad. Sci. U. S. A. 90:1993;6671-6675.
9. Casares S., Bona C.A., Brumeanu T.D. Engineering and characterization of a murine MHC class II-immunoglobulin chimera expressing an immunodominant CD4 T viral epitope. Protein Eng. 10:1997;1295-1301.
10. Malherbe L., Filippi C., Julia V., Foucras G., Moro M., Appel H., Wucherpfennig K., Guery J.C., Glaichenhaus N. Selective activation and expansion of high-affinity CD4+ T cells in resistant mice upon infection with Leishmania major. Immunity. 13:2000;771-782.
11. Bercovici N., Duffour M.T., Agrawal S., Salcedo M., Abastado J.P. New methods for assessing T-cell responses. Clin. Diagn. Lab. Immunol. 7:2000;859-864.
12. Whiteside T.L. Monitoring of antigen-specific cytolytic T lymphocytes in cancer patients receiving immunotherapy. Clin. Diagn. Lab. Immunol. 7:2000;327-332.
13. Selin L.K., Lin M.Y., Kraemer K.A., Pardoll D.M., Schneck J.P., Varga S.M., Santolucito P.A., Pinto A.K., Welsh R.M. Attrition of T cell memory: selective loss of LCMV epitope-specific memory CD8 T cells following infections with heterologous viruses. Immunity. 11:1999;733-742.
14. Kern F., Bunde T., Faulhaber N., Kiecker F., Khatamzas E., Rudawski I.M., Pruss A., Gratama J.W., Volkmer-Engert R., Ewert R., Reinke P., Volk H.D., Picker L.J. Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. J. Infect. Dis. 185:2002;1709-1716.
15. Yee C., Savage P.A., Lee P.P., Davis M.M., Greenberg P.D. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J. Immunol. 162:1999;2227-2234.
16. Hernandez J., Lee P.P., Davis M.M., Sherman L.A. The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire. J. Immunol. 164:2000;596-602.
17. Baurain J.F., Colau D., van Baren N., Landry C., Martelange V., Vikkula M., Boon T., Coulie P.G. High frequency of autologous anti-melanoma CTL directed against an antigen generated by a point mutation in a new helicase gene. J. Immunol. 164:2000;6057-6066.
18. Jager E., Nagata Y., Gnjatic S., Wada H., Stockert E., Karbach J., Dunbar P.R., Lee S.Y., Jungbluth A., Jager D., Arand M., Ritter G., Cerundolo V., Dupont B., Chen Y.T., Old L.J., Knuth A. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc. Natl. Acad. Sci. U. S. A. 97:2000;4760-4765.
19. Pittet M.J., Valmori D., Dunbar P.R., Speiser D.E., Lienard D., Lejeune F., Fleischhauer K., Cerundolo V., Cerottini J.C., Romero P. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J. Exp. Med. 190:1999;705-715.
20. Meidenbauer N., Marienhagen J., Laumer M., Vogl S., Heymann J., Andreesen R., Mackensen A. Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients. J. Immunol. 170:2003;2161-2169.
21. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R., Restifo N.P., Hubicki A.M., Robinson M.R., Raffeld M., Duray P., Seipp C.A., Rogers-Freezer L., Morton K.E., Mavroukakis S.A., White D.E., Rosenberg S.A. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 298:2002;850-854.
22. Mackensen A., Herbst B., Chen J.L., Kohler G., Noppen C., Herr W., Spagnoli G.C., Cerundolo V., Lindemann A. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int. J. Cancer. 86:2000;385-392.
23. Lee K.H., Wang E., Nielsen M.B., Wunderlich J., Migueles S., Connors M., Steinberg S.M., Rosenberg S.A., Marincola F.M. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J. Immunol. 163:1999;6292-6300.
24. Gillespie G.M., Wills M.R., Appay V., O'Callaghan C., Murphy M., Smith N., Sissons P., Rowland-Jones S., Bell J.I., Moss P.A. Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors. J. Virol. 74:2000;8140-8150.
25. Riddell S.R., Walter B.A., Gilbert M.J., Greenberg P.D. Selective reconstitution of CD8+ cytotoxic T lymphocyte responses in immunodeficient bone marrow transplant recipients by the adoptive transfer of T cell clones. Bone Marrow Transplant. 14(4 Suppl.):1994;S78-S84.
26. Walter E.A., Greenberg P.D., Gilbert M.J., Finch R.J., Watanabe K.S., Thomas E.D., Riddell S.R. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333:1995;1038-1044.
27. Heslop H.E., Brenner M.K., Rooney C.M. Donor T cells to treat EBV-associated lymphoma. N. Engl. J. Med. 331:1994;679-680.
28. Heslop H.E., Ng C.Y., Li C., Smith C.A., Loftin S.K., Krance R.A., Brenner M.K., Rooney C.M. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat. Med. 2:1996;551-555.
29. Brodie S.J., Lewinsohn D.A., Patterson B.K., Jiyamapa D., Krieger J., Corey L., Greenberg P.D., Riddell S.R. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat. Med. 5:1999;34-41.
30. Rosenberg S.A., Packard B.S., Aebersold P.M., Solomon D., Topalian S.L., Toy S.T., Simon P., Lotze M.T., Yang J.C., Seipp C.A.et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 319:1988;1676-1680.
31. Oelke M., Maus M.V., Didiano D., June C.H., Mackensen A., Schneck J.P. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat. Med. 9:2003;619-625.
32. Aalamian M., Pirtskhalaishvili G., Nunez A., Esche C., Shurin G.V., Huland E., Huland H., Shurin M.R. Human prostate cancer regulates generation and maturation of monocyte-derived dendritic cells. Prostate. 46:2001;68-75.
33. Heiser A., Coleman D., Dannull J., Yancey D., Maurice M.A., Lallas C.D., Dahm P., Niedzwiecki D., Gilboa E., Vieweg J. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Invest. 109:2002;409-417.
34. Oelke M., Moehrle U., Chen J.L., Behringer D., Cerundolo V., Lindemann A., Mackensen A. Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy. Clin. Cancer Res. 6:2000;1997-2005.
35. Abbas A.K., Murphy K.M., Sher A. Functional diversity of helper T lymphocytes. Nature. 383:1996;787-793.
36. Romagnani S. Th1 and Th2 in human diseases. Clin. Immunol. Immunopathol. 80:1996;225-235.
37. Irinyi B., Aleksza M., Antal-Szalmas P., Sipka S., Hunyadi J., Szegedi A. Cytokine production of CD4+ and CD8+ peripheral T lymphocytes in patients with chronic idiopathic urticaria. Acta Derm.-Venereol. 82:2002;249-253.
38. Kemp R.A., Ronchese F. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity. J. Immunol. 167:2001;6497-6502.
39. Cerwenka A., Morgan T.M., Harmsen A.G., Dutton R.W. Migration kinetics and final destination of type 1 and type 2 CD8 effector cells predict protection against pulmonary virus infection. J. Exp. Med. 189:1999;423-434.
40. Oelke M., Kurokawa T., Hentrich I., Behringer D., Cerundolo V., Lindemann A., Mackensen A. Functional characterization of CD8(+) antigen-specific cytotoxic T lymphocytes after enrichment based on cytokine secretion: comparison with the MHC-tetramer technology. Scand. J. Immunol. 52:2000;544-549.
41. Maus M.V., Thomas A.K., Leonard D.G., Allman D., Addya K., Schlienger K., Riley J.L., June C.H. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat. Biotechnol. 20:2002;143-148.
42. Takahashi C., Mittler R.S., Vella A.T. Differential clonal expansion of CD4 and CD8 T cells in response to 4-1BB ligation: contribution of 4-1BB during inflammatory responses. Immunol. Lett. 76:2001;183-191.
43. Latouche J.B., Sadelain M. Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells. Nat. Biotechnol. 18:2000;405-409.
44. D'Souza S., Rimoldi D., Lienard D., Lejeune F., Cerottini J.C., Romero P. Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype. Int. J. Cancer. 78:1998;699-706.
45. Laderach D., Movassagh M., Johnson A., Mittler R.S., Galy A. 4-1BB co-stimulation enhances human CD8(+) T cell priming by augmenting the proliferation and survival of effector CD8(+) T cells. Int. Immunol. 14:2002;1155-1167.